BioLineRx Corp (BLRX) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization

Graphic logo of BioLineRx Corp (BLRX)

The BioLineRx Ltd. (BLRX) business model is based on the promotion of Aphexda, with the primary growth drivers being the reach of transplant centers and trials for the treatment of pancreatic tumors. The product's integration into hematological practice accelerates stem cell collection, establishing the method as an industry standard. The market trend reflects an EV/EBITDA value of 0.00. Stable management is successfully expanding insurance reimbursements in the US, strengthening shareholder confidence.

BLRX BioLineRx Ltd: Enterprise Value to Operating Income Before Depreciation in the range 11/23/2025 - 11/10/2026

BLRX (biolinerx.com): analytical breakdowns and indicator data

- stock price and consensus target price:
Stock Quotes BioLineRx Corp|BLRX - Fair Value Consensus
- market capitalization indicators:
Market Value BioLineRx Corporation|BLRX - Total Enterprise Value
- book value of equity indicators:
Net Assets per Single Share BioLineRx|BLRX - Accounting Capitalization|Market Capitalization to Book Value Ratio biolinerx.com|BLRX - Cumulative Company Assets
- debt and liquidity data:
Debt to Equity BioLineRx Ltd.|BLRX - Long-Term Liabilities to Capital|Short-Term Debt to Equity BioLineRx|BLRX - Company Debts|Debt to Book Capitalization Ratio BioLineRx Corporation|BLRX - Long-Term Debt|Company Short-Term Debts BioLineRx|Quick Liquidity Indicator biolinerx.com
- business earnings and investment ratios data:
BLRX - Company Net Income|Future Profit BioLineRx Ltd.|BLRX - Company Value to Net Income|Projected Price to Earnings BioLineRx Ltd.|BLRX - Company Value to Earnings Growth Ratio|EV/EBITDA Multiple BioLineRx Corporation|BLRX - Income before deduction of interest, taxes and amortization|Net earnings per share (EPS TTM) BioLineRx|BLRX - Net earnings per one share for the last twelve months|Year-over-year earnings per share growth for the last twelve months biolinerx.com|BLRX - Earnings per share increase in current year|Earnings growth forecast for next year BioLineRx Ltd.
Summary company analytics:BLRX (BioLineRx Corp)
Original product of BioLineRx

Fundamental asset screening requires analyzing business value relative to its ability to generate earnings before interest, taxes, depreciation, and amortization. An EV/EBITDA multiple valuation compares the total capitalization of BioLineRx Ltd. (BLRX) with its operating cash flow, where stable figures confirm the company's resilience amid the commercialization of its stem cell drug and the minimization of liquidity risks.

Competitor analysis

Incyte Corp. - Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation HCM|NUVB - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to EBITDA dayonebio.com|Monopar Therapeutics Inc. (MNPR) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to Operating Income Before Depreciation INBX|IMAB (I-Mab Biopharma Co., Ltd.) - EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio Fennec (FENC)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Heron Therapeutics (HRTX)|NVCT - Company Value to EBITDA|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Coherus BioSciences Inc. CHRS|Corbus Pharmaceuticals Holdings, Inc. - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|CRDF - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to EBITDA BeyondSpring Inc|BCAB: EV/EBITDA Multiple|Enterprise Value to EBITDA Multiple lixte.com LIXT|Enterprise Value to EBITDA Ratio CTXR|Company Value to EBITDA Cellectar Biosciences Inc CLRB|Enterprise Value to EBITDA Ratio CANF (Can-Fite BioPharma, Ltd.)|APRE (aprea.com) - Business Value to Operating Income Before Depreciation|Kazia Therapeutics Limited - Enterprise Value to EBITDA Ratio|Enterprise Value to Operating Income Before Depreciation Ratio SLXN (Silexion Therapeutics Corp.)|NuCana Corp - EV/EBITDA Multiple|Business Value to Operating Income Before Depreciation CMRX (Chimerix Inc.)|CYCC: EV/EBITDA Multiple|Company Value to EBITDA G1 Therapeutics (GTHX)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Kronos Bio, Inc.|KTRA: Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple ONCT|EV/EBITDA Multiple Portage Biotech Inc (PRTG)